Endocrine Abstracts

Since the first somatostatin receptor ligand (SRL) was used to treat acromegaly, predicting which patients could benefit from their use has become crucial to avoid months of ineffective treatment for non-responding patients. Although many biomarkers linked to SRL response have been identified, there is no consensus criterion on how to prescribe according to biomarker levels. In this study, we evaluate previously reported biomarkers using more exhaustive and accurate methods th...

We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression. Methods: Patients from the ACROFAS...